RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Medical Devices

Therapeutics

RVL Pharmaceuticals

RVL Pharmaceuticals' headquarters in Bridgewater, NJ, United States

Brian Markison

Kristin Comer

Katerina G.

Nick Fee

Danielle Scandone

Jd Schaub

James Schaub

Andrew Einhorn

Description

People (8)

Michael Battaglia

Nicole Domanski-Rudnik

Deana Confalone-Sanchez

Joann Stavole

Ada Tinescu

Jd Schaub

Jordan Mathews

Nick Fee

Jobs